Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz Sells 20,000 Shares of Stock

Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $33.91, for a total value of $678,200.00. Following the sale, the director now owns 3,402,584 shares in the company, valued at approximately $115,381,623.44. This represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Simulations Plus Stock Up 4.0 %

NASDAQ SLP opened at $35.50 on Wednesday. The stock’s 50-day simple moving average is $30.56 and its two-hundred day simple moving average is $32.42. Simulations Plus, Inc. has a twelve month low of $24.00 and a twelve month high of $51.22. The company has a market capitalization of $713.20 million, a price-to-earnings ratio of 88.75 and a beta of 0.82.

Hedge Funds Weigh In On Simulations Plus

Large investors have recently modified their holdings of the company. Barclays PLC grew its stake in shares of Simulations Plus by 390.6% during the third quarter. Barclays PLC now owns 28,473 shares of the technology company’s stock valued at $911,000 after buying an additional 22,669 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Simulations Plus by 4.4% during the 3rd quarter. Geode Capital Management LLC now owns 448,618 shares of the technology company’s stock valued at $14,367,000 after acquiring an additional 18,924 shares during the period. State Street Corp grew its position in Simulations Plus by 4.7% during the 3rd quarter. State Street Corp now owns 640,303 shares of the technology company’s stock worth $20,503,000 after acquiring an additional 28,953 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Simulations Plus by 106.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 47,365 shares of the technology company’s stock worth $1,517,000 after purchasing an additional 24,371 shares during the period. Finally, BNP Paribas Financial Markets lifted its position in Simulations Plus by 402.9% in the third quarter. BNP Paribas Financial Markets now owns 39,944 shares of the technology company’s stock valued at $1,279,000 after purchasing an additional 32,002 shares during the last quarter. 78.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. BTIG Research reduced their price objective on shares of Simulations Plus from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. William Blair restated an “outperform” rating on shares of Simulations Plus in a research report on Wednesday, January 8th. StockNews.com downgraded Simulations Plus from a “hold” rating to a “sell” rating in a research report on Monday, November 4th. KeyCorp boosted their target price on Simulations Plus from $35.00 to $37.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Finally, Stephens assumed coverage on Simulations Plus in a report on Friday, November 15th. They issued an “overweight” rating and a $39.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $49.40.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.